Apontis Pharma AG (FRA:APPH)
Germany
· Delayed Price · Currency is EUR | Market Cap | 89.96M |
| Revenue (ttm) | 48.47M |
| Net Income (ttm) | 753.57K |
| Shares Out | n/a |
| EPS (ttm) | 0.09 |
| PE Ratio | 119.38 |
| Forward PE | 33.32 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10 |
| Average Volume | 6 |
| Open | 10.70 |
| Previous Close | 10.50 |
| Day's Range | 10.55 - 10.70 |
| 52-Week Range | 6.12 - 12.20 |
| Beta | n/a |
| RSI | 43.52 |
| Earnings Date | Aug 8, 2025 |
About Apontis Pharma AG
Apontis Pharma AG engages in the marketing and sale of medical drugs for indication fields of internal medicine in Germany. It offers single pills and other pharmaceutical products with a focus on cardiovascular diseases, such as hypertension, hyperlipidemia, and secondary prophylaxis, as well as respiratory diseases and diabetes. The company was founded in 1946 and is based in Monheim am Rhein, Germany. As of November 21, 2024, Apontis Pharma AG operates as a subsidiary of Zentiva AG. [Read more]
Financial Performance
Financial StatementsNews
EQS-Adhoc: APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
EQS-Ad-hoc: APONTIS PHARMA AG / Key word(s): Squeeze Out APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40 13-Jun-2025 / 10:30 CET/CEST Disclosure of an inside informatio...
APONTIS PHARMA: Big 2024 Gains & Merger Plans Ahead!
APONTIS PHARMA has surged ahead with a remarkable 31.1% sales increase, signaling a transformative year for the company. With revenues climbing to EUR 48.5 million and a significant EBITDA turnaround,...
EQS-News: APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned
EQS-News: APONTIS PHARMA AG / Key word(s): Annual Report/Annual Results APONTIS PHARMA with significant sales and earnings increase in 2024 financial year – squeeze-out and merger planned 31.03.2025 /...